TSX Shariah screener · October 2026
Microbix Biosystems Inc.
Is Microbix Biosystems Inc. (MBX) Halal?
Microbix Biosystems Inc. · TSX: MBX · Healthcare
Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.
The short answer
Microbix Biosystems Inc. (TSX: MBX) is a PASS. The business gate passes: it is a Mississauga life-sciences manufacturer of diagnostic antigens (used by ~100 diagnostics makers) and quality-assessment products (PROCEEDx, ReDx, QUANTDx) sold in 30+ countries, plus royalties and the Kinlytic urokinase biosimilar program — with no prohibited segments. The debt gate passes: long-term debt of C$5.36M (June 30, 2026) is about 13.0% of the ~C$41.1M market cap (138,986,931 shares × C$0.31, October 1, 2026), well under the ~33% ceiling. The income gate passes: separately disclosed interest income of C$529,444 in the audited FY2024 financial statements is about 2.08% of FY2024 revenue of C$25.4M (1.76% in H1 FY2026), well under the ~5% ceiling. Cash of C$7.2M (June 30, 2026) is about 17.5% of market cap. No Zoya, Musaffa, or ShariaPortfolio coverage was found. This is a rules-based screen, not a religious ruling.
Gate 1 — Business activity: PASS
Microbix is a human-health life-sciences manufacturer and exporter (ISO 9001/13485, FDA/TGA/Health Canada registered) with three revenue lines: diagnostic antigens — native and recombinant antigens for immunoassays used by ~100 diagnostics makers (Q3 FY2026: C$2.19M, +20% year over year); QAPs — PROCEEDx, ReDx, and QUANTDx reference materials for clinical-lab proficiency testing and assay validation, sold in 30+ countries (Q3 FY2026: C$1.72M, +13%); and royalties/inbound licensing. The company also owns the global rights to Kinlytic urokinase (a biologic thrombolytic with existing FDA/Health Canada approvals) and is developing a biosimilar version, with an FDA comparability-protocol meeting expected before year-end 2026. There are no alcohol, gambling, weapons, tobacco, cannabis, conventional-lending/insurance, or pork segments. The business gate passes.
Gate 2 — Debt and cash: PASS
Interest-bearing debt at June 30, 2026 (Q3 FY2026) was C$5.36M — long-term debt of C$5.35M plus the current portion of C$0.01M. The debt mix is convertible debentures (about C$4M face, held by private individuals, convertible at C$0.23) plus BDC mortgage/FedDev/TD financing, with a C$4M revolving credit line at a Canadian chartered bank undrawn in recent quarters. Against a market cap of ~C$41.1M (138,986,931 shares outstanding × C$0.31, October 1, 2026, TSX), that is about 13.0% — well under the ~33% ceiling (C$1.36M of lease liabilities are excluded per the screen’s methodology). Cash of C$7.2M at June 30, 2026 is about 17.5% of market cap — also under the ~33% ceiling. The debt and cash gates pass.
Gate 3 — Non-compliant income: PASS
Interest income is a separately disclosed line (“Financial Expenses, net” note), not netted away. The audited FY2024 financial statements (filed December 19, 2024) show interest income of C$529,444 against FY2024 revenue of C$25.4M — about 2.08%. The H1 FY2026 interim statements show C$133,887 against revenue of C$7.6M — about 1.76%. Both are well under the ~5% ceiling. (The company pays interest on its debentures; that does not affect this gate.) The income gate passes.
BDS screen
Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.
No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).
Moral screen
Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.
- Israeli military business
- No findings published.
- US military business
- No findings published.
- Weapons manufacturing & arms trade
- No findings published.
Key figures used
- PASS — all gates pass (October 2026 screen)
- Business: Mississauga diagnostics maker (antigens, QAPs sold in 30+ countries) + Kinlytic urokinase biosimilar program; no prohibited segments — PASS
- Debt: C$5.36M (Jun 30, 2026: LT debt C$5.35M + current portion C$0.01M) ≈ 13.0% of ~C$41.1M market cap (138,986,931 shares × C$0.31, Oct 1, 2026) vs ~33% ceiling — PASS
- Income: ≈2.08% — audited FY2024 interest income C$529,444 ÷ revenue C$25.4M vs ~5% ceiling (H1 FY2026: ≈1.76%) — PASS
- Cash: C$7.2M (Jun 30, 2026) ≈ 17.5% of market cap
- Third-party: no Zoya/Musaffa/ShariaPortfolio coverage found
- Material: no dividends (retained-cash policy); NCIB share buybacks active through Dec 8, 2026; qualified as supplier to five major diagnostic test makers (~Sep 2026); Kinlytic biosimilar: FDA comparability meeting expected by end-2026
Frequently asked questions
Is Microbix Biosystems (MBX) halal?
Our October 2026 screen gives Microbix Biosystems Inc. (TSX: MBX) a PASS. The business gate passes (Mississauga life-sciences manufacturer of diagnostic antigens used by ~100 diagnostics makers, plus quality-assessment products sold in 30+ countries and the Kinlytic urokinase biosimilar program; no prohibited segments). The debt gate passes (long-term debt of C$5.36M at June 30, 2026 is about 13.0% of the ~C$41.1M market cap, well under the ~33% ceiling). The income gate passes (separately disclosed interest income of C$529,444 in the audited FY2024 statements is about 2.08% of FY2024 revenue of C$25.4M, well under the ~5% ceiling; 1.76% in H1 FY2026). Cash of C$7.2M is about 17.5% of market cap. No Zoya, Musaffa, or ShariaPortfolio coverage was found. This is a rules-based screen, not a religious ruling.
What does Microbix Biosystems do?
Microbix is a Mississauga human-health life-sciences manufacturer and exporter (ISO 9001/13485, FDA/TGA/Health Canada registered) with three revenue lines: diagnostic antigens — native and recombinant antigens for immunoassays used by ~100 diagnostics makers (Q3 FY2026: C$2.19M, +20% year over year); QAPs — PROCEEDx, ReDx, and QUANTDx reference materials for clinical-lab proficiency testing and assay validation, sold in 30+ countries (Q3 FY2026: C$1.72M, +13%); and royalties/inbound licensing. The company also owns the global rights to Kinlytic urokinase (a biologic thrombolytic with existing FDA/Health Canada approvals) and is developing a biosimilar version, with an FDA comparability-protocol meeting expected before year-end 2026.
How much debt does Microbix Biosystems have?
Interest-bearing debt at June 30, 2026 (Q3 FY2026) was C$5.36M — long-term debt of C$5.35M plus the current portion of C$0.01M. The debt mix is convertible debentures (about C$4M face, held by private individuals, convertible at C$0.23) plus BDC mortgage/FedDev/TD financing, with a C$4M revolving credit line at a Canadian chartered bank undrawn in recent quarters. Against a market cap of ~C$41.1M (138,986,931 shares outstanding × C$0.31, October 1, 2026, TSX), that is about 13.0% — well under the ~33% ceiling (C$1.36M of lease liabilities are excluded per the screen’s methodology).
Is Microbix Biosystems’ income compliant?
Yes. Interest income is a separately disclosed line (“Financial Expenses, net” note), not netted away. The audited FY2024 financial statements (filed December 19, 2024) show interest income of C$529,444 against FY2024 revenue of C$25.4M — about 2.08%. The H1 FY2026 interim statements show C$133,887 against revenue of C$7.6M — about 1.76%. Both are well under the ~5% ceiling. (The company pays interest on its debentures; that does not affect this gate.) The income gate passes.
What do third-party Shariah screeners say about MBX?
No Zoya, Musaffa, or ShariaPortfolio rating was found for MBX in public search — none of the three named providers surfaced coverage, so no rating is claimed here.
Sources
- Microbix — FY2024 audited annual financial statements (December 19, 2024; interest income C$529,444; revenue C$25.4M)
- StockTitan — Microbix Q3 FY2026 results (August 13, 2026; cash C$7.2M; long-term debt C$5.35M)
Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).